Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Nearly a year ago, Viking Therapeutics (NASDAQ ... The injectable version of the candidate, tentatively named VK2735, reduced obesity patients' weight by 14.7% after 13 weeks in a relatively ...

Riley lowered the firm’s price target on Viking Therapeutics (VKTX ... earnings call “particularly encouraged” by the oral VK2735 delivering on “injectables’-like” weight loss data ...

Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ ... especially impressed by the strong results from its potential weight loss asset VK2735, which could ...

Viking Therapeutics traded as low as $31.00 and last traded at $30.97. 886,719 shares traded hands during trading, a decline of 77% from the average session volume of 3,895,525 shares. The stock ...